IPEC Releases Revised Excipient Information Package Guidance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

IPEC Releases Revised Excipient Information Package Guidance

ePT--the Electronic Newsletter of Pharmaceutical Technology

The 2013 Excipient Information Package (EIP) User Guide is now available for free download from the International Pharmaceutical Excipients Council (IPEC)-Americas website. The revised guide updates the 2005 version and can be used by excipient suppliers to provide a standardized set of documents to exchange data between suppliers and their customers.

The EIP is similar to a Material Safety Data Sheet (MSDS) with designated sections to include specified data on specific topics. The guide is intended to assist individuals experienced in evaluating excipient suppliers but is not a replacement for audits, the organization reports.

The IPEC-Americas Regulatory Reference page, located on the IPEC-Americas website, contains links to the specific regulatory references applicable in different regions to provide additional guidance on specific topics.

Use of the EIP documents can help streamline information and data in a simple formalized and consistent manner to reduce the volume of questionnaires and surveys needed to obtain similar information from multiple customers, according to an IPEC-Americas statement.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here